These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6436732)

  • 21. Effect of valproate, sodium 2-propyl-4-pentenoate and sodium 2-propyl-2-pentenoate on renal substrate uptake and ammoniagenesis in the rat.
    Elhamri M; Ferrier B; Martin M; Baverel G
    J Pharmacol Exp Ther; 1993 Jul; 266(1):89-96. PubMed ID: 8331578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproate-induced hyperammonemia: role of diet.
    Marescaux C; Warter JM; Rumbach L; Micheletti G; Chabrier G; Imler M
    World Rev Nutr Diet; 1984; 43():174-8. PubMed ID: 6433563
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hyperammonemia during sodium valproate therapy: clinically relevant or accidental finding?].
    Ettlin T; Scollo-Lavizzari G
    Schweiz Rundsch Med Prax; 1986 Jul; 75(29):881-5. PubMed ID: 3090672
    [No Abstract]   [Full Text] [Related]  

  • 25. [Encephalopathy associated with hyperammonemia in an alcoholic patient treated with sodium valproate].
    Mattei A; Bernard G; Plauchu G; Paliard P
    Gastroenterol Clin Biol; 1993; 17(6-7):516-7. PubMed ID: 8243949
    [No Abstract]   [Full Text] [Related]  

  • 26. [Renal glutamine metabolism in man during treatment with sodium valproate].
    Warter JM; Marescaux C; Chabrier G; Rumbach L; Micheletti B; Imler M
    Rev Neurol (Paris); 1984; 140(5):370-1. PubMed ID: 6431585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
    Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valproate acute administration, EEG epileptic abnormalities, and ammonemia.
    Sannita WG
    Neurology; 1992 Oct; 42(10):2003-5. PubMed ID: 1407583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
    Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
    Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures.
    Petroff OA; Rothman DL; Behar KL; Hyder F; Mattson RH
    Seizure; 1999 Apr; 8(2):120-7. PubMed ID: 10222306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe acute hyperammonemia after brief exposure to valproate.
    Eubanks AL; Aguirre B; Bourgeois JA
    Psychosomatics; 2008; 49(1):82-3. PubMed ID: 18212182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency.
    Leão M
    Neurology; 1995 Mar; 45(3 Pt 1):593-4. PubMed ID: 7898728
    [No Abstract]   [Full Text] [Related]  

  • 35. Valproate, hyperammonaemia, and hyperglycinaemia.
    Jaeken J; Casaer P; Corbeel L
    Lancet; 1980 Aug; 2(8188):260. PubMed ID: 6105420
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of induced hyperammonemia on renal ammonia metabolism.
    OWEN EE; JOHNSON JH; TYOR MP
    J Clin Invest; 1961 Feb; 40(2):215-21. PubMed ID: 13731806
    [No Abstract]   [Full Text] [Related]  

  • 37. Valproic acid and secondary hyperammonemia.
    Rawat S; Borkowski WJ; Swick HM
    Neurology; 1981 Sep; 31(9):1173-4. PubMed ID: 6791053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of circulatory antioxidants by alpha-ketoglutarate during sodium valproate treatment in Wistar rats.
    Murugesan V; Subramanian P
    Pol J Pharmacol; 2003; 55(1):31-6. PubMed ID: 12856823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
    Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
    J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute valproate intoxication: biochemical investigations and hemodialysis treatment.
    Mortensen PB; Hansen HE; Pedersen B; Hartmann-Andersen F; Husted SE
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):64-8. PubMed ID: 6404845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.